CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clin Infect Dis. 2022 Aug 24;75(1):e1165-e1175. doi: 10.1093/cid/ciab1007.
Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory condition in persons aged <21 years associated with antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to describe MIS-C cases reported to Centers for Disease Control and Prevention's (CDC's) national surveillance since the coronavirus disease 2019 (COVID-19) pandemic began.
We included patients meeting the MIS-C case definition with onset date from 19 February 2020 through 31 July 2021, using CDC's MIS-C case report form, which collects information on demographics, clinical presentation, and laboratory results. Trends over time across 3 MIS-C pandemic waves were assessed using Cochran-Armitage test for categorical and Jonckheere-Terpstra test for continuous variables.
Of 4901 reported cases, 4470 met inclusion criteria. Median patient age increased over time (P < .001), with a median of 9 years (interquartile range, 5-13 years) during the most recent (third) wave. Male predominance also increased (62% in third wave, P < .001). A significant (P < .001) increase in severe hematologic and gastrointestinal involvement was observed across the study period. Frequency of several cardiovascular complications (ie, cardiac dysfunction, myocarditis, and shock/vasopressor receipt) and renal failure declined (P < .001). Provision of critical care including mechanical ventilation (P < .001) and extracorporeal membrane oxygenation (ECMO; P = .046) decreased, as did duration of hospitalization and mortality (each P < .001).
Over the first 3 pandemic waves of MIS-C in the United States, cardiovascular complications and clinical outcomes including length of hospitalization, receipt of ECMO, and death decreased over time. These data serve as a baseline for monitoring future trends associated with SARS-CoV-2 B.1.617.2 (Delta) or other variants and increased COVID-19 vaccination among children.
儿童多系统炎症综合征(MIS-C)是 21 岁以下人群中与严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染相关的一种严重超炎症状态。我们的目的是描述自 2019 年冠状病毒病(COVID-19)大流行开始以来,疾病预防控制中心(CDC)国家监测系统报告的 MIS-C 病例。
我们纳入了发病日期为 2020 年 2 月 19 日至 2021 年 7 月 31 日、符合 MIS-C 病例定义的患者,使用 CDC 的 MIS-C 病例报告表,该表收集了人口统计学、临床表现和实验室结果的信息。使用 Cochran-Armitage 检验对分类变量和 Jonckheere-Terpstra 检验对连续变量进行了 3 次 MIS-C 大流行波的时间趋势评估。
在报告的 4901 例病例中,有 4470 例符合纳入标准。中位患者年龄随时间推移而增加(P<.001),在最近(第三波)波中为 9 岁(四分位距,5-13 岁)。男性优势也增加(第三波中为 62%,P<.001)。在整个研究期间,严重血液学和胃肠道受累的发生率显著增加(P<.001)。几种心血管并发症(即心功能障碍、心肌炎和休克/血管加压药的使用)和肾功能衰竭的频率下降(P<.001)。包括机械通气(P<.001)和体外膜氧合(ECMO;P=.046)在内的重症监护的提供减少,住院时间和死亡率降低(均 P<.001)。
在美国 MIS-C 的前 3 个大流行波中,心血管并发症和临床结局(包括住院时间、ECMO 的使用以及死亡)随时间推移而降低。这些数据为监测与 SARS-CoV-2 B.1.617.2(Delta)或其他变体以及儿童 COVID-19 疫苗接种率增加相关的未来趋势提供了基线。